Feasibility pilot in limited cutaneous systemic sclerosis: 43 patients were randomised to mycophenolate mofetil or no immunosuppression, below the 60 needed to continue, so the trial was stopped; no clinical worsening events occurred.
RCTn = 43
Denton et al. A randomised open-label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot)